SCHEMBL311892

SCHEMBL311892

O=c1cc(-c2ccc(O)cc2)oc2nccc(O)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.58
AR P10275 6/20 0.58
MAPT P10636 5/20 0.58
CYP3A4 P08684 5/20 0.58
HPGD P15428 4/20 0.58
MEN1 O00255 4/20 0.58
MAPK1 P28482 3/20 0.58
RAF1 P04049 1/20 0.58
TDP1 Q9NUW8 4/20 0.55
KDM4E B2RXH2 4/20 0.55
IP6K2 Q9UHH9 4/20 0.55
NPC1 O15118 4/20 0.55
PKM P14618 3/20 0.55
GABRP O00591 3/20 0.55
GABRD O14764 3/20 0.55
GABRA1 P14867 3/20 0.55
GABRB1 P18505 3/20 0.55
GABRG2 P18507 3/20 0.55
GABRB3 P28472 3/20 0.55
GABRA5 P31644 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311671 0.79 KMT2A (0.52) KMT2AARMAPTCYP3A4HPGD
SCHEMBL311589 0.79 CYP3A4 (0.49) KMT2AARMAPTCYP3A4HPGD
SCHEMBL311484 0.78 MAPT (0.60) KMT2AARMAPTCYP3A4HPGD
SCHEMBL312444 0.77 CDK5 (0.54) KMT2AARMAPTCYP3A4HPGD
SCHEMBL311324 0.77 NPC1 (0.60) KMT2AARMAPTCYP3A4HPGD
SCHEMBL23299597 0.75 CDK5 (0.72) KMT2AARMAPTCYP3A4HPGD
SCHEMBL157490 0.74 AR (1.00) KMT2AARMAPTCYP3A4HPGD
SCHEMBL312751 0.72 MAPT (0.59) KMT2AARMAPTCYP3A4HPGD
Apigenin SCHEMBL19428 0.71 KMT2A (1.00) KMT2AARMAPTCYP3A4HPGD
SCHEMBL29636735 0.71 LCK (0.78) KMT2AARMAPTCYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 KMT2A 2842/4885AR 2406/4885MAPT 2914/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 KMT2A 2842/4885AR 2406/4885MAPT 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.